Delivery Order SPE2DR25D2206-SPE2DR26F9DC7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $12,467 to AmerisourceBergen Drug Corp on November 24, 2025, for the supply of SKYRIZI 360 mg/2.4 mL on-body injection units. This competitively awarded, firm fixed-price delivery order is set to be completed by December 16, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting the contractor's demonstrated capability to...
- The Defense Logistics Agency awarded a $12,467 delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of SKYRIZI 360 MG/2.4 ML on-body injectable medication. This firm fixed price delivery order, which is not set-aside, will be performed at the contractor's corporate office in Conshohocken, Pennsylvania, with completion required by December 1, 2025. The award represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with the...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,467.00 for SKYRIZI 360 mg/2.4 mL on-body injectors on December 15, 2025. This firm fixed-price delivery order is scheduled for completion by January 7, 2026 and represents a non-set-aside competitive award. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a $12,467.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 MG/2.4 ML on-body 2.4ML injectable medication on October 22, 2025, with completion targeted for November 13, 2025. This non-set-aside delivery order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with the Defense Logistics Agency,...
- The Defense Logistics Agency awarded a delivery order valued at $12,467.00 to AmerisourceBergen Drug Corp for SKYRIZI 360 mg/2.4 ml on-body injectable medication. This is a firm fixed-price, non-set-aside contract awarded on October 27, 2025, with a completion deadline of November 18, 2025. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a $12,467.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 mg/2.4 mL on-body injection units on December 8, 2025. The delivery order, which represents a child contract under AmerisourceBergen's larger DLA relationship, requires completion by December 30, 2025, and will be performed at the company's headquarters in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation....
- The Defense Logistics Agency awarded a $12,467 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 12, 2026, for the supply of SKYRIZI 360 MG/2.4 ML on-body injectable medication. The order is set to be completed by February 3, 2026, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at...
- The Defense Logistics Agency awarded a $12,467.00 firm fixed price delivery order to AmerisourceBergen Drug Corp on November 14, 2025, for the supply of SKYRIZI 360 mg/2.4 mL on-body 2.4 mL injections, with completion required by December 8, 2025. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a $12,467 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 13, 2026, for the supply of SKYRIZI 360 mg/2.4 mL on-body injectable medication. The contract, with a completion date of February 4, 2026, will be fulfilled from the vendor's facilities in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s...
- The Defense Logistics Agency awarded a $11,830 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 mL on-body injectable medication in 2.4 mL quantities. The award, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, was made without a set-aside designation through competitive procurement. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9DC7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $12,467.00 to AmerisourceBergen Drug Corp on November 24, 2025, for the supply of SKYRIZI 360 MG/2.4 ML on-body injectable medication. This firm fixed-price delivery order, with an ultimate completion date of December 16, 2025, represents a non-set-aside competitive award to support federal medical procurement needs. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's significant indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare systems and other federal agencies including the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen's established position as a major pharmaceutical distributor demonstrates its capability to fulfill federal medical supply requirements across multiple therapeutic domains through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.5k | 11/23/25 |